|
|
Myriad Genetics (MYGN)
Website: www.Myriad.com "Myriad has the deepest diagnostic pipeline across the disease spectrum." Myriad Genetics (Nasdaq: MYGN) is a biopharmaceutical with a low debt to assets ratio and a very promising pipeline. The company has been hit hard over the last year and has been shorted quite heavily. With earnings out, the stock is looking to rebound off its 52 week low and and we feel that a classic short squeeze will be in for the near term. Myriad Genetics (MYGN) is a personalized medicine company, that focuses on the development and marketing of predictive, personalized, and prognostic medicine tests worldwide. It operates through two segments, Diagnostics and Other. The Diagnostics segment primarily provides testing and collaborative development of testing that is designed to assess an individuals risk for developing disease; identify a patients likelihood of responding to drug therapy; guide a patients dosing to ensure optimal treatment; and assess a patients risk of disease progression and disease recurrence. The Other segment provides testing products and services to the pharmaceutical, biotechnology, and medical research industries; and research and development, and clinical services for patients. Its molecular diagnostic DNA sequencing tests include myRisk Hereditary cancer, a test for hereditary cancers; BRACAnalysis and BART, which are tests for hereditary breast and ovarian cancers; BRACAnalysis CDx test for use in identifying ovarian cancer patients with suspected deleterious germline; and Tumor BRACAnalysis CDx test that is used to predict DNA damaging agents, such as platinum based chemotherapy agents and poly ADP ribose inhibitors. The company also provides COLARIS test for colorectal and uterine cancers; COLARIS AP test for colorectal cancer; Vectra DA protein detection test for assessing the disease activity of rheumatoid arthritis; Prolaris, a RNA expression test for prostate cancer; EndoPredict RNA expression test for breast cancer; myPath Melanoma RNA expression test for diagnosing melanoma; myChoice homologous recombination deficiency (HRD) test to measure three modes of HRD; and myPlan lung cancer, an RNA expression test for lung cancer. Myriad Genetics, Inc. has collaboration with AstraZeneca for the development of an indication for BRACAnalysis CDx. The company was founded in 1991 and is headquartered in Salt Lake City, Utah.
Recent News and Press Releases Myriad Genetics Launches the EndoPredict® Test in the United States for Patients with Breast Cancer Myriad Genetics Reports Fiscal Second-Quarter 2017 Financial Results Myriad beats Street 2Q forecasts For the latest Quote and News on MYGN Click Here. Mark C. Capone - President and Chief Executive Officer Mark C. Capone is President and CEO of Myriad Genetics. He previously served as President of Myriad Genetic Laboratories from March 2010 to June 2015. Mr. Capone joined the company in October 2002. Prior to joining Myriad, he served 17 years with Eli Lilly and Company where he held positions as Product Development Manager, Manufacturing Plant Manager, and Area Sales Director. Mr. Capone received his B.S. degree in Chemical Engineering from Penn State University graduating with highest distinction and his M.S. degree in Chemical Engineering from Massachusetts Institute of Technology. He also earned a Master of Science in Management from the Sloan School of Management at the Massachusetts Institute of Technology. In 2012, Mr. Capone was elected Outstanding Engineering Alumnus at Penn State and he is a member of the Industrial and Professional Advisory Council at Penn State. He currently serves on the Board of the American Clinical Laboratory Association. Mr. Capone also is a Member of the Board of Trustees for Pioneer Theatre Company in Salt Lake City. Patrick Burke - Executive Vice President, Emerging Products Patrick Burke, executive vice president of emerging products, joined the company in 2001. In his current role, he oversees New Product Planning, Business Development and Project Management. Previously, Dr. Burke served as Vice President of Strategic Collaborations and held positions of increasing responsibility within the Business and Corporate Development group at Myriad. Between 2009 and 2011, he served as Vice President of Corporate and Business Development at Myrexis, Inc., a subsidiary of the company. Dr. Burke is an active member of Licensing Executive Society and the Association of University Technology Managers. He earned his Ph.D. in Cell Biology from the University of Utah School of Medicine and his B.A. in Molecular Biology from the University of California, San Diego. Virginia C. Drosos - President, Assurex Health Virginia “Gina” C. Drosos, president of Assurex Health, joined the Company in 2013. Previously, she grew global brand portfolios in the consumer goods and personal care industries at Procter & Gamble for 25 years. Ms. Drosos was group president for Global Beauty Care, a $6 billion business with 6,000 employees in 120 countries and 50 brands, including CoverGirl, Old Spice, Pantene and Olay, which grew from less than $200 million to more than $2.5 billion in sales under her leadership. Twice recognized as one of Fortune’s 50 Most Powerful Women in Business, Ms. Drosos was also recently named 2015 Corporate Woman of the Year by the Cincinnati Chamber of Commerce and one of Cincinnati’s “16 for 2016” top business leaders. Under her leadership, Assurex Health was recognized as one of Inc. magazine’s 50 Fastest Growing Women-Led Companies in America and USA Today’s Top 10 Entrepreneurial Companies. Ms. Drosos holds a B.S. in Business Administration from The Terry School, University of Georgia, and an M.B.A. from The Wharton School, University of Pennsylvania. She serves on the boards of directors of Signet Jewelers, Ltd. and American Financial Group. Alexander Ford - President, Myriad Genectic Laboratories Alexander Ford, President of Myriad Genetic Laboratories, joined the company in June 2010. Before being named to his current position, he served as Chief Commercial Officer. Prior to joining Myriad, Mr. Ford held leadership positions at Novartis, Sanofi-Aventis, Nektar Therapeutics and Pfizer in the areas of Marketing Research, Product Marketing, Managed Care, Sales and Business Development. He has more than 25 years of experience in the pharmaceutical and biotechnology industries. Mr. Ford received his B.A. degree in Communications from the University of North Carolina, Wilmington and his M.A. degree from New York University. He was a founding board member for BioUtah and was voted Sales Executive of the Year by the Utah Technology Council in 2012.
Myriad Genetics 320 Wakara Way 801-584-3600
SmallCapReview.com
feature stock reports are intended to be stock ideas, not recommendations.
Please do your own research before investing. It is crucial that you at
least look at current SEC filings and read the latest press releases.
Information contained in this report was extracted from current documents
filed with the SEC, the company website and other publicly available sources
deemed reliable. For more information see our disclaimer section, a link of
which can be found on our website. This document contains forward-looking
statements, particularly as related to the business plans of the Company,
within the meaning of Section 27A of the Securities Act of 1933 and Sections
21E of the Securities Exchange Act of 1934, and is subject to the safe
harbor created by these sections. Actual results may differ materially from
the Company's expectations and estimates. The information provided in this
report is not intended for distribution to, or use by, any person or entity
in any jurisdiction or country where such distribution or use would be
contrary to law or regulation or which would subject us to any registration
requirement within such jurisdiction or country. Copyright SmallCapReview. All rights reserved. SCR is not a Registered Broker/Dealer or Financial Advisor. All materials presented on our website and individual reports released to the public through this website, e-mail or any other means of transmission are not to be regarded as investment advice and are only for informative purposes. Before making a purchase or sale of any securities featured on our web site or mentioned in our reports, we strongly encourage and recommend consultation with a registered securities representative. This is not to be construed as a solicitation or recommendation to buy or sell securities. Past performance of our profiled stocks is not indicative of future results. The profile and opinions expressed herein are expressed as of the date the profile is posted on site and are subject to change without notice. No investor should assume that reliance on the views, opinions or recommendations contained herein will produce profitable results. SmallCapReview may hold positions in securities mentioned herein, and may make purchases or sales in such securities featured on our website or within our reports In order to be in full compliance with the Securities Act of 1933, Section 17(b), SCR will disclose in it's disclaimer, what, if any compensation was received for our efforts in researching, presenting and disseminating this information to our subscriber database and featuring the report on the SmallCapReview website. SmallCapReview has not been compensated for its efforts with regards to Myriad Genetics. As with any stock, companies we select to profile involve a degree of investment risk and volatility, particularly small-caps. All investors are cautioned that they may lose all or a portion of their investment if they decide to make a purchase in any of our profiled companies. We encourage our readers to invest carefully and read the investor information available at the web sites of the Securities and Exchange Commission (SEC) at: http://www.sec.gov and/or the National Association of Securities Dealers (NASD) at: http://www.nasd.com . Readers can review all public filings by companies at the SEC's EDGAR page. The NASD has published information on how to invest carefully at its website. |
